This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Bioject Reports Unaudited Year-End And Quarterly 2012 Financial Results

As part of the Agreement, the Company has agreed to conduct an exchange offer, as soon as practicable, to the existing holders of Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (the “Lettered Stock”), for a new series of preferred stock (the “New Series”). The New Series would not be convertible into Common Stock, would not have voting rights and would not have a regular dividend. The New Series would have a mandatory redemption date of August 1, 2015, for the current stated value of the Lettered Stock. The New Series would retain all the liquidation preferences and protective provisions of the Lettered Stock. If the mandatory redemption payment is not made, the New Series will begin accruing a penalty dividend of four percent, (4%) payable in cash or additional New Series stock. In addition, the Purchasers of the Series H Preferred Stock will be offered the right to exchange the Series H Preferred Stock for the New Series at any time prior to August 1, 2015.

Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.

Readers and potential investors are cautioned that an investment in the Company’s securities involves an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that audited financial results may differ materially from the unaudited results reported in this press release, the risk that the Company may be unable to continue operations and may file bankruptcy, the risk that the Company’s products will not be accepted by the market, the risk that the Company will be unable to successfully develop and negotiate new strategic relationships, uncertainties related to the time required for the Company to complete research and development, obtain necessary clinical data and government clearances, the risk that additional capital may not be available on acceptable terms, if at all, the risk that the Company may not receive orders, whether anticipated or unanticipated, the risk that the Company’s proposed supply chain management process improvement may not be implemented or may not improve the Company’s cash position or cash flows, and the risk that the Company may be unable to comply with the extensive government regulations applicable to the business.

Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com .

For more information about Bioject, visit www.bioject.com

Bioject Medical Technologies Inc.

Selected Condensed Consolidated Statements of Operations Data (Unaudited)

(In thousands, except share and per share data)

   

 

Three months ended

December 31,

  Year ended

December 31,

  2012       2011       2012       2011  
RESULTS OF OPERATIONS:    
 
Revenue and Expense:
Net sales $ 111 $ 795 $ 1,955 $ 8,075
Operating expenses   614       2,169       2,977       8,907  
Operating loss (503 ) (1,374 ) (1,022 ) (832 )
Other expense, net   (6 )     (21 )     (32 )     (47 )
Net loss (509 ) (1,395 ) (1,054 ) (879 )
Preferred stock dividend   (72 )     (26 )     (138 )     (104 )
Net loss allocable to common shareholders

$

(581

)

 

$

(1,421

)

  $ (1,192 )   $ (983 )
 
Basic and diluted net loss per common share allocable to common shareholders (rounded)

 

 

$

 

 

(0.03

 

 

)

 

 

 

$

 

 

(0.08

 

 

)

 

 

 

$

 

 

(0.06

 

 

)

 

 

 

$

 

 

(0.05

 

 

)

Shares used in per share calculations  

18,908,594

     

18,908,594

     

18,908,594

     

18,733,459

 
 
 

For the 2012 three months ended,

March 31,   June 30,   September 30,   December 31,
RESULTS OF OPERATIONS:      
 
Revenue and Expense:
Net sales $ 979 $ 353 $ 512 $ 111
Operating expenses   878       635       850       614  
Operating income (loss) 101 (282 ) (338 ) (503 )
Other expense, net   (11 )     (9 )     (6 )     (6 )

Net Income (loss)

90 (291 ) (344 ) (509 )
Preferred stock dividend   (30 )     (30 )     (6 )     (72 )
Net income (loss) allocable to common shareholders

$

60

   

$

(321

)

  $ (350 )  

$

(581

)

 
Basic net income (loss) per common share allocable to common shareholders

 

$

 

0.00

   

 

$

 

(0.02

 

)

 

 

$

 

(0.02

 

)

 

 

$

 

(0.03

 

)

Shares used in basic per share calculations  

18,908,594

     

18,908,594

     

18,908,594

     

18,908,594

 
Diluted net income (loss) per common share allocable to common shareholders

 

 

$

 

 

0.00

   

 

 

$

 

 

(0.02

 

 

)

 

 

 

$

 

 

(0.02

 

 

)

 

 

 

$

 

 

(0.03

 

 

)

Shares used in diluted per share calculations  

38,034,636

     

18,908,594

     

18,908,594

     

18,908,594

 
 
Bioject Medical Technologies Inc.

Selected Condensed Consolidated Balance Sheet Data (Unaudited)

(In thousands)

   
December 31,
  2012       2011  

ASSETS

Current assets $ 724 $ 1,810
Property and equipment, net 95 371
Other assets, net   1,412       1,363  
Total assets $ 2,231     $ 3,544  
 

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

Current liabilities $ 2,532 $ 2,653
Long term liabilities 982 1,167
Shareholders’ equity (deficit):
Preferred stock 9,622 9,484
Common stock 115,032 114,985
Accumulated deficit   (125,937 )     (124,745 )
Total shareholders’ deficit   (1,283 )     (276 )
Total liabilities and shareholders’ deficit $ 2,231     $ 3,544  




2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs